Short interest for Adynxx gives investors a sense of the degree to which investors are betting on the decline of Adynxx's stock. Short interest data is updated every two weeks.

Adynxx Stock Short Interest Report | OTC:ADYX | Benzinga

Adynxx

Overview

News

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Comments

Adynxx Short Interest Report

Adynxx Stock Short Interest Report | OTC:ADYX | Benzinga